Evidence map›Paper›PMID 40873587›Full record

ArticleFrontiers in immunology2025

Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring

Yan Meng, Yanping Du, Xiaolin Liu, Jue Huang, Hanhan Chen, Chunxia He

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan Meng *Department of Medical Oncology, 2nd District, Hainan Cancer Hospital, Hainan, China.
Yanping Du *The School of Clinical Medicine, Fujian Medical University, Fuzhou,, China.
Xiaolin LiuGuangzhou University of Chinese Medicine, Guangzhou, China.
Jue HuangDepartment of Medical Oncology, 2nd District, Hainan Cancer Hospital, Hainan, China.
Hanhan ChenDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Chunxia HeGuangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, University of Guangzhou Traditional Chinese Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with Methods: We reported treatment information and outcomes of four patients with metastatic NSCLC harboring Results: All the four patients had metastatic lung adenocarcinoma and reached partial response to T-DXd treatment. A 57-year-old female patient with Conclusion: The potential of T-DXd in patients with metastatic NSCLC harboring

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungErb-b2 Receptor Tyrosine KinasesImmunoconjugatesLung NeoplasmsMutationTrastuzumabCamptothecinExonsFemaleHumansMaleMiddle AgedNeoplasm MetastasisTreatment OutcomeAntineoplastic Agents, ImmunologicalCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabtrastuzumab deruxtecancase serieshuman epidermal growth factor receptor 2mutationnon-small cell lung cancertrastuzumab deruxtecan

Identifiers

PMID40873587
PMCPMC12378165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.